Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject (DUAL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02159599 |
Recruitment Status :
Completed
First Posted : June 10, 2014
Last Update Posted : February 14, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infection | Drug: Darunavir/Ritonavir Drug: Lamivudine Drug: Emtricitabine/tenofovir or abacavir/lamivudine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 249 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppressed Plasma Viremia |
Study Start Date : | July 2014 |
Actual Primary Completion Date : | April 2016 |
Actual Study Completion Date : | April 2016 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Darunavir/Ritonavir + 2 nucleos(t)idos
Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
|
Drug: Darunavir/Ritonavir
Darunavir/ritonavir (800/100 mg): QD (quaque die )
Other Name: Prezista/Norvir Drug: Emtricitabine/tenofovir or abacavir/lamivudine Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
Other Name: Truvada or Kivexa |
Experimental: Darunavir/ritonavir + Lamivudine
Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
|
Drug: Darunavir/Ritonavir
Darunavir/ritonavir (800/100 mg): QD (quaque die )
Other Name: Prezista/Norvir Drug: Lamivudine Lamivudine (300mg) : QD
Other Name: Epivir |
- Proportion of patients with undetectable viral load [ Time Frame: week 48 ]Undetectable viral load <50 copies/ml according to the FDA snapshot algorithm
- Proportion of patients with undetectable viral load [ Time Frame: Week 24 ]Undetectable viral load < 50 copies/ml according to the FDA snapshot algorithm
- Proportion of patients with viral load < 200 copies/ml [ Time Frame: week 48 ]Proportion of patients with viral load < 200 copies/ml according to FDA snapshot algorithm
- Proportion of patients who present viral load ≥ 50 copies /ml one time [ Time Frame: From basal visit until week 48 visit ]Viral load ≥ 50 copies/ml
- Proportion of patients who present viral load ≥ 50 copies /ml more tan two times [ Time Frame: From basal visit until week 48 visit ]Viral load ≥ 50 copies /ml
- Proportion of patients who maintained viral load < 50 copies/ml in all determinations [ Time Frame: week 48 ]Viral load < 50 copies/ml
- Median of change cells CD4/µl count from basal to week 48 [ Time Frame: week 48 ]CD4/µl
- Median of change in triglycerides , LDL-cholesterol, HDL-cholesterol and total cholesterol from basal to week 48 [ Time Frame: week 48 ]
- Change in renal function [ Time Frame: week 48 ]Change in glomerular filtration
- Change in proportion of patients with renal tubular dysfunction [ Time Frame: week 48 ]
- Proportion of genotypic resistance mutations [ Time Frame: Week 48 ]Mutations in patients viral failure
- Change in proportion of genotypic resistance mutations [ Time Frame: week 48 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acceptance to participate in the study, signing the informed consent document before conducting any study procedures.
- Patient with HIV infection older than 18 years.
- Treatment with darunavir/ritonavir once a day and tenofovir/emtricitabine or abacavir/lamivudine during at least 4 weeks at the moment of the screening
- Plasma HIV RNA levels below 50 copies / ml for at least 6 months (two separate measurements at least 6 months with viremia <50 copies / ml between both).
- HbsAg negative
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Evidence of Lamivudine resistance (any previous genotype with mutation M184V/I or K65R) and/or to darunavir (population genotype show any of the following mutations: V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, T74P, L76V, I84V, L89V).
-
History of virology failure (two consecutive viral loads above 200 copies/ml) while the patient was receiving a regimen with lamivudine or emtricitabine, with the following exceptions:
- Do not consider an exclusion criterion if the genotype performed at the time of failure does not demonstrate resistance to lamivudine and darunavir (see criteria 2).
- Do not consider an exclusion criteria in the absence of genotype if after the episode turns to maintain a viral load <50 copies / ml with a treatment composed of lamivudine or emtricitabine + a nucleoside + a non-nucleoside.
-
History of abandonment of treatment including lamivudine or emtricitabine, with the following exception:
- Viral load prior to abandonment was <50 copies / ml and subsequent reintroduction of the same treatment or another treatment consisting of lamivudine or emtricitabine + a nucleoside + a non-nucleoside returns to maintain viral load below 50 copies / ml .
- Previous treatment with bitherapy or monotherapy with lamivudine or emtricitabine
- Previous treatment with bitherapy or monotherapy with a regimen with a protease inhibitor that is terminated by viral rebound, when the absence of a genotypic resistance test available after viral rebound allow discard the resistance mutations either drug used.
- The use of concomitant medication not permitted
- Presence of active acute infection, including opportunist infection that a judge of investigator that can difficult the participation in the trial
- Any laboratory results of the following: hemoglobin<8,0 g/dl; neutrophils <750 cells/µl; platelets <50.000 cell/µl; creatinine ≥ 1,5 ULN (upper limit of normal)
- Any clinical or analytic event that, in the investigator judgment, condition the patient safety

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02159599

Study Director: | Jose R Arribas, MD | Hospital Universitario La Paz | |
Study Director: | Federico Pulido, MD | Hospital Universitario 12 de Octubre | |
Study Director: | Esteban Ribera, MD | Hospital Vall d'Hebron |
Responsible Party: | Fundacion SEIMC-GESIDA |
ClinicalTrials.gov Identifier: | NCT02159599 |
Other Study ID Numbers: |
GESIDA 8014 2014-000515-14 ( EudraCT Number ) |
First Posted: | June 10, 2014 Key Record Dates |
Last Update Posted: | February 14, 2017 |
Last Verified: | June 2016 |
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Darunavir Tenofovir Lamivudine Emtricitabine |
Abacavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |